Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.55 |
| ▸ | AHR | P35869 | 1/20 | 0.49 |
| ▸ | TSPO | P30536 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAP2 | P11137 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15330508 | 0.91 | PTGS2 (0.47) | PTGS2AHRLMNA | |
| SCHEMBL15330541 | 0.91 | MEN1 (0.55) | PTGS2AHRTSPOLMNA | |
| SCHEMBL11584079 | 0.91 | PTGS2 (0.55) | PTGS2AHRMAP2 | |
| SCHEMBL15332589 | 0.89 | PTGS2 (0.48) | PTGS2AHRTSPOLMNA | |
| SCHEMBL15330822 | 0.88 | PTGS2 (0.44) | PTGS2AHR | |
| SCHEMBL15331347 | 0.88 | PTGS2 (0.47) | PTGS2TSPOLMNA | |
| SCHEMBL15331697 | 0.87 | PTGS2 (0.47) | PTGS2AHRTSPO | |
| SCHEMBL15329923 | 0.87 | AHR (0.44) | PTGS2AHRLMNAMAP2 | |
| SCHEMBL2560887 | 0.86 | MEN1 (0.47) | PTGS2AHRLMNA | |
| SCHEMBL15330369 | 0.86 | PTGS2 (0.53) | PTGS2AHRLMNAMAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| US-20010039286-A1 | 2-aryl indole derivatives and their use as therapeutic agents | DINNELL KEVIN (GB) | 2001-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039286-A1 | 2-aryl indole derivatives and their use as therapeutic agents | IDO1, IDO2, CNR2 | PTGS2 42/4885AHR 346/4885TSPO 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.